Angiogenic and immunoglobic applications of anti cd160 specific compounds obtainable from mab cl 1-r2

Abstract

The present invention relates to biological and medical application of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) an of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD 160 compounds in the fields of EC angiogenesis, and NK and T cytokine production

1 - 53 . (canceled) 
     
     
         54 . Drug comprising Anti-CD160 compound selected from the group consisting of anti-CD160 mAb CL1-R2 obtainable from the hybridoma deposited as CNCM I-3204, a conservative fragment of said mAb CL1-R2 and a conservative derivative of said mAb CL1-R2 comprising at least one CL1-R2 fragment, wherein said anti-CD160 compound is capable of competing with the anti-CD160 mAb CL1-R2 for binding to CD160, and is sufficiently CD160-specific for binding to CD160 without binding to at least CD8αβ. 
     
     
         55 . Drug according to  claim 54 , wherein said anti-CD160 compound does further not bind to CD85j. 
     
     
         56 . Drug according to  claim 54 , wherein said anti-CD160 compound is a conservative fragment of said mAb CL1-R2 selected from the group consisting of a Fab, a Fab′, a F(ab) 2 , a F(ab′) 2  and a Fv fragment of said mAb CL1-R2. 
     
     
         57 . Drug according to  claim 54 , wherein said anti-CD160 compound is a conservative derivative of said mAb CL1-R2, which comprises at least one scFv compound comprising at least one CL1-R2 VH region of CL1-R2 linked to at least one CL1-R2 VL region of CL1-R2 via a peptide linker (L). 
     
     
         58 . Drug according to  claim 57 , wherein said conservative derivative is a monovalent scFv. 
     
     
         59 . Drug according to  claim 57 , wherein said conservative derivative is a multivalent scFv. 
     
     
         60 . Drug according to  claim 54 , wherein said anti-CD160 compound is a conservative derivative of said mAb CL1-R2 which comprises a scFv multimer derived from said CL1-R2 mAb, joined to a Fc fragment. 
     
     
         61 . Drug according according to  claim 54 , wherein said anti-CD160 compound is a conservative derivative of said mAb CL1-R2 which comprises at least one Fv fragment of CL1-R2 linked to a human Fc. 
     
     
         62 . Drug according to  claim 54 , wherein said anti-CD160 compound is a conservative derivative, of said mAb CL1-R2 obtainable by adding one or more Fab derived from said CL1-R2 mAb at the C-terminus of each H chain of the full length CL1-R2 mAb. 
     
     
         63 . Drug according to  claim 54 , wherein said anti-CD160 compound is a conservative derivative of said mAb CL1-R2 obtainable by covalently linking full-length CL1-R2 mAbs together to form an aggregated Ab form. 
     
     
         64 . Drug according to  claim 54 , wherein said anti-CD160 compound is a conservative derivative of said mAb CL1-R2 obtainable by linking two or more Fabs head-to-tail. 
     
     
         65 . Drug according to  claim 54 , wherein said anti-CD160 compound further comprises an immunotoxin and/or a radioelement. 
     
     
         66 . Drug according to  claim 54 , wherein said anti-CD160 compound is a soluble compound. 
     
     
         67 . Drug according to  claim 54 , wherein said anti-CD160 compound is a compound comprising at least one CD160 binding site and at least one CD158b binding site. 
     
     
         68 . Drug according to  claim 54 , wherein said anti-CD160 compound is an aggregated compound. 
     
     
         69 . Drug according to  claim 68 , wherein said aggregated compound comprises a least three CD160 binding sites and no CD158b binding site. 
     
     
         70 . A method of treating angiogenesis in an individual comprising administering to said animal an anti-CD160 drug composition according to  claim 54 . 
     
     
         71 . The method of  claim 70 , wherein said anti-angiogenic drug is administered for the prevention or treatment of a tumor. 
     
     
         72 . The method of  claim 70 , wherein said anti-angiogenic drug is administered for the prevention or treatment of pre-eclampsia or eclampsia. 
     
     
         73 . The method of  claim 70 , wherein said anti-angiogenic drug is administered for the prevention or treatment diabetes, and/or an ischemic ocular disease, and/or rheumatoid arthritis. 
     
     
         74 . A method of inducing or up-regulating the adaptive immunity potential of an individual comprising administering to said individual an anti-CD160 composition as defined in  claim 68 . 
     
     
         75 . The method of  claim 74 , wherein said drug is administered for the treatment or prevention of an infection. 
     
     
         76 . The method of  claim 74 , wherein said drug is part of a vaccine composition, or is provided as a vaccine adjuvant. 
     
     
         77 . A method of inducing or up-regulating hematopoiesis in an individual comprising administering to said individual an anti-CD160 composition of  claim 68 . 
     
     
         78 . A method of inducing or up regulating an inflammatory reaction in an individual comprising administering to said individual an effective amount of an anti-CD160 composition of  claim 68 . 
     
     
         79 . A method of inhibiting or down-regulating the adaptive immunity potential of an individual comprising administering to said individual an anti-CD160 composition of  claim 66 . 
     
     
         80 . A method of inhibiting or down-regulating hematopoiesis in an individual comprising administering an anti-CD 60 composition of  claim 66 . 
     
     
         81 . A method of inhibiting or down-regulating an inflammatory reaction in an individual comprising administering to said individual of an anti-CD160 composition of  claim 66 . 
     
     
         82 . A method of treating B-cell chronic lymphocytic leukaemia in an individual comprising administering to said subject an anti-CD160 composition of  claim 54 .